IPCA Laboratories Ltd

Stage 2 · Advancing · week 40Setup 4.8 WatchSolid +0.8

As of 9 Oct 2026, IPCA Laboratories is in Stage 2 — advancing, the uptrend phase, in week 40 (since 1 Jan 2026). It closed at ₹1,915, 4.7% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, A… More about the company

₹1,915.4
-1.19% today
₹48,595 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

4.8 Watch

Momentum

Steady

Edge

Solid +0.8

Setup-score rank among Stage 2 peers: #35 of 61 in Pharmaceuticals · #42 of 78 in Health Care

Is IPCALAB early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-4.7%
₹1,268.7 lo₹2,010.3 hi
4.7% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 40
1w13w26w
Week 40 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
16.7%
200 DMA: ₹1,641.5 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.22x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -0.6% vs MA50 +3.4%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-2.6%
3M
+7.1%
6M
+32.6%
YTD
+34.1%
1Y
+43.0%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #23 of 74 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #20 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-13 → 2026-10-09
S2 43w
S2 24w
S2 40w
2023-07-132026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 5w → S2 43w → S3 7w → S2 24w → S3 8w → S4 9w → S1 4w → S4 3w → S1 9w → S4 10w → S1 5w → S2 40w current
Total tracked: 169 weeks across 13 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-01-01
2 appearances in last 60 days. First seen: 2024-08-16.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 40 · Vol 0.22x
2026-10-08S2
Wk 40 · Vol 0.76x
2026-10-07S2
Wk 39 · Vol 0.32x
2026-10-06S2
Wk 39 · Vol 0.65x
2026-10-05S2
Wk 39 · Vol 0.50x
2026-10-01S2
Wk 39 · Vol 0.78x
2026-09-30S2
Wk 39 · Vol 0.75x
2026-09-29S2
Wk 38 · Vol 0.59x
2026-09-28S2
Wk 38 · Vol 0.41x
2026-09-25S2
Wk 38 · Vol 0.61x
2026-09-24S2
Wk 38 · Vol 0.64x
2026-09-23S2
Wk 38 · Vol 0.37x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,899.4
200 DMA
₹1,641.5
52W High
₹2,010.3
52W Low
₹1,268.7
5D Low
₹1,915.4
Resistance levels (recent highs)
20d High
₹2,010.3
60d High
₹2,010.3
120d High
₹2,010.3
250d High
₹2,010.3
Next resistance
+5.0%
to 20d High
Ask the Market AI about IPCALABAsk →
P/E (TTM)
43.9
Forward 29.1
Earnings Growth (YoY)
+23.6%
Revenue +6.6%
Dividend Yield
0.25%
P/B 4.8
About this companyHealth Care· Pharmaceuticals

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.